JACC This Week ACS Guidelines | Maturation of Lipid Management | JACC
Jun 3, 2025
Kausik Ray, a Professor of Public Health and Cardiologist at Imperial College London, discusses the 2025 ACC/AHA Acute Coronary Syndrome guidelines. He emphasizes the revolutionary shift from solely using statins to embracing combination therapies for lipid management. The conversation highlights the necessity of initiating these combinations—statins, ezetimibe, and PCSK9 inhibitors—simultaneously for high-risk patients. This approach aims to bridge the gap between clinical practice and evidence-based strategies, ultimately improving patient outcomes.
AI Snips
Chapters
Transcript
Episode notes
Guidelines Shift to Combination Therapy
- The 2025 ACC/AHA ACS guidelines advance from statin monotherapy to endorsing early combination therapies.
- Risk-enhancing features prompt therapy intensification even if LDL cholesterol is 55-69 mg/dl, not just the absolute LDL threshold.
Any LDL Lowering Reduces Events
- Trials show LDL lowering by diverse agents, including PCSK9 inhibitors and bempedoic acid, reduces cardiovascular events.
- The specific treatment method matters less than achieving substantial LDL reduction.
LDL Target and Treatment Gaps
- Achieving LDL targets below 55 mg/dl is critical post-acute coronary syndrome.
- Majority of ACS patients are lipid-lowering naive, and 80% won't reach LDL targets on statins alone without combination therapy.